Docket Number:11A-1060914
Inventor:Ching-Shih Chen, Chia-Hsien Wu, I-Shan Hsieh, Po-Hsien Huang
IP Status:World country patent pending
Abstract:
In this invention, we have developed a series of novel CREB inhibitors via the screening of a focused compound library, followed by lead optimization. These inhibitors disrupt the interaction between CREB and CBP, leading to the proteasomal degradation of CREB and/or CBP and the downregulation of an array of CREB target gene products.
Fields of Application:
These inhibitors can be used for treating a number of diseases, most notably cancer, pancreatic and liver fibrosis, and acute alcohol-induced liver steatosis.
Advantages when compared to the existing technologies:
The invention provides a possible treatment direction for a number of diseases, most notably cancer, pancreatic and liver fibrosis.
Contact Person:
對本技術有興趣,請於本處網頁廠商選項下(廠商需求與諮詢)網頁填寫資料,承辦人將跟您聯絡。
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Apply for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office, and the undertaker will contact you.
